Moreover, retrospective analyses [12,14] and a clinical trial [20] have demonstrated that the use of RAS inhibitors improves survival in metastatic CCRCC patients receiving VEGF-targeted therapy. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.